Location of Repository

Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.

By Maria de Lourdes Farre Vallve, Achilea Candida Lisboa Bittencourt, Gilvanéia Silva Santos, A. Almeida, A. C. Silva, Daniele Decanine, G. M. Soares, Luiz Carlos Júnior Alcantara, Sonia Van Dooren, Bernardo Galvão Castro Filho, Anne-Mieke Vandamme and Johan Van Weyenbergh

Abstract

Fas (TNFRSF6/Apo-1/CD95) is a type I transmembrane receptor, which mediates apoptosis. Fas gene mutations, aberrant transcripts, and abundant expression of Fas have been reported in adult T cell leukemia (ATL). To further elucidate the role of Fas in ATL pathogenesis, we investigated whether the –670 FAS promoter A/G polymorphism (STAT1- binding site) might contribute to susceptibility and clinical outcome in ATL. Thirty-one patients with ATL, 33 healthy, human T lymphotropic virus type 1-infected individuals, and 70 healthy, uninfected controls were genotyped for the FAS –670 polymorphism by PCR-restriction fragment-length polymorphism. The AA genotype was significantly over-represented in ATL patients in comparison with healthy controls (P 0.006), as well as asymptomatics (P 0.037), corresponding to an odds ratio (OR) of 3.79 [95% confidence intervals (CI; 1.28–11.41)] and 4.58 [95% CI (1.13–20.03)], respectively. The AA group also comprised significantly more aggressive (acute and lymphoma) clinical subtypes [P 0.012; OR 8.40; 95% CI (1.60–44.12)]. In addition, we observed a statistically significant association between GG genotype and survival (log rank test, P 0.032). Finally, IFN- -induced but not basal FAS mRNA levels were increased significantly (P 0.049) in PBMCs from AA versus GG individuals, demonstrating the IFNdependent functionality of the –670 polymorphism. In conclusion, our results demonstrate that a functional Fas promoter polymorphism is significantly associated to susceptibility, clinical manifestation, and survival in ATL

Topics: TNFRSF6, ATL, STAT1, HTLV-1, Apoptosis, Antígenos CD95/genética, Predisposição Genética para Doença/genética, Leucemia de Células T/genética, Polimorfismo de Nucleotídeo Único/genética, Regiões Promotoras Genéticas/genética, Antígenos CD95/imunologia, Seguimentos, Genótipo, Infecções por HTLV-I/imunologia, Humanos, Interferon gama/farmacologia, Leucemia de Células T/diagnóstico, Leucócitos Mononucleares/efeitos de drogas, RNA Mensageiro/genética, Fatores de Risco, Taxa de Sobrevida
Publisher: Society for Leukocyte Biology
Year: 2007
OAI identifier: oai:agregador.ibict.br.RI_FIOCRUZ:oai:localhost:icict/8115
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.rcaap.pt/detail.jsp... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.